News

Integrated care overcomes HCV treatment barriers


 

FROM CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

References

Patients with hepatitis C and psychiatric disorders or substance abuse problems benefit significantly from an integrated care model of treatment, with a randomized controlled trial showing such an approach is linked to greater rates of antiviral therapy and treatment response.

The prospective trial of integrated care versus usual care involved 363 patients attending three hepatitis C (HCV) clinics, with the integrated care being delivered by a midlevel mental health provider within the clinic who served as the regular contact and case manager.

Patients randomized to integrated care, which included brief psychological interventions and case management, were more than twice as likely to start antiviral therapy earlier and achieve a sustained virologic response than those who received usual care, according to Dr. Samuel B. Ho of the VA San Diego Healthcare System and his coauthors.

While individuals with a history of prior psychiatric disorder or active drug use were significantly less likely to achieve sustained virologic response, the integrated-care approach had particularly positive effects on treatment initiative and response for individuals with a risk for active psychiatric disease at baseline, they said (Clin Gastroenterol Hepatol. 2015. doi: 10.1016/j.cgh.2015.02.022).

“To optimize the public health impact of antiviral treatments for HCV, the number of patients who are able to receive these treatments must be expanded,” wrote Dr. Ho and his associates, adding that “new interferon-free regimens have fewer side effects and are expected to expand treatment populations to include a broader range of patients, many with very significant psychiatric and substance abuse disorders.”

The study was supported by VA Health Services Research and Development. Three authors declared research support, grants, advisory board positions or speakers bureau roles with the pharmaceutical industry.

AGA Resource
Through the AGA Roadmap to the Future of Practice, AGA offers a Hepatitis C Clinical Service line to support high-quality patient care at www.gastro.org/patient-care/conditions-diseases/hepatitis-c.

Recommended Reading

FDA sued for access to data on hepatitis C medications
MDedge Family Medicine
Daclatasvir plus sofosbuvir safe and effective in HCV/HIV coinfection
MDedge Family Medicine
Online resource provides updated HCV tx guidelines
MDedge Family Medicine
Ledipasvir-sofosbuvir plus ribavirin in advanced HCV does well
MDedge Family Medicine
FDA approves Daklinza for HCV genotype 3 infections
MDedge Family Medicine
FDA approves oral interferon-free treatment for genotype 4 HCV infection
MDedge Family Medicine
Cirrhosis in HCV often goes unreported
MDedge Family Medicine
Less posttransplant primary biliary cirrhosis with preventive UDCA
MDedge Family Medicine
Subclinical heart dysfunction, fatty liver linked
MDedge Family Medicine
Virologic response no protection against HCV liver decompensation
MDedge Family Medicine